Artax Biopharma

Artax Biopharma is a company headquartered in the United States. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 3 investors associated with the company.

Artax Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of T cell-mediated autoimmune diseases. The company develops first-in-class oral small molecules that modulate T cell activation through Nck binding to the T cell receptor, aiming to restore healthy immune responses without causing immunosuppression.